FDA Approves Corbus Phase 2 Trial Extension of Systemic Sclerosis Drug Resunab

Author: Kara Elam
Date Published: April-2016
Source: Lung Disease News

Corbus Pharmaceuticals, a clinical stage company targeting rare, chronic inflammatory and fibrotic diseases, recently received approval by the U.S. Food and Drug Administration (FDA) for a 12-month open-label extension trial of the ongoing Phase 2 study testing Resunab as a therapy for diffuse cutaneous systemic sclerosis.